Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer

BACKGROUND: We sought to characterize response to immune checkpoint inhibitor (ICI) in non-squamous non-small cell lung cancer (NSCLC) across various CD274 copy number gain and loss thresholds and identify an optimal cutoff. MATERIALS AND METHODS: A de-identified nationwide (US) real-world clinico-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Murugesan, Karthikeyan, Jin, Dexter X, Comment, Leah A, Fabrizio, David, Hegde, Priti S, Elvin, Julia A, Alexander, Brian, Levy, Mia A, Frampton, Garrett M, Montesion, Meagan, Roychowdhury, Sameek, Kurzrock, Razelle, Ross, Jeffrey S, Albacker, Lee A, Huang, Richard S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Cancer Diagnostics and Molecular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438920/
https://www.ncbi.nlm.nih.gov/pubmed/35598202
http://dx.doi.org/10.1093/oncolo/oyac096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438920/
https://www.ncbi.nlm.nih.gov/pubmed/35598202
http://dx.doi.org/10.1093/oncolo/oyac096

Ejemplares similares